Multicenter, Double-Blind, Randomized, Placebo-ControlledStudy to Evaluate Safety, Tolerability, and Efficacy ofIxekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-to-Severe Plaque Psoriasis